[HTML] sciencedirect.com

[HTML][HTML] Comparative effectiveness and safety of direct oral anticoagulants vs warfarin among obese patients with atrial fibrillation

LA Boivin-Proulx, BJ Potter, M Dorais, S Perreault - CJC open, 2022 - Elsevier
Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …
被引用次数：7 相关文章
[HTML] nih.gov

[HTML][HTML] Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin Among Obese Patients With Atrial Fibrillation

LA Boivin-Proulx, BJ Potter, M Dorais, S Perreault - CJC Open, 2022 - ncbi.nlm.nih.gov
Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …

Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin Among Obese Patients With Atrial Fibrillation

LA Boivin-Proulx, BJ Potter, M Dorais… - CJC open, 2022 - pubmed.ncbi.nlm.nih.gov
Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …

Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin Among Obese Patients With Atrial Fibrillation.

LA Boivin-Proulx, BJ Potter, M Dorais, S Perreault - CJC Open, 2022 - europepmc.org
Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …
[HTML] cjcopen.ca

[HTML][HTML] Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin Among Obese Patients With Atrial Fibrillation

LA Boivin-Proulx, BJ Potter, M Dorais, S Perreault - CJC Open, 2022 - cjcopen.ca
Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …